TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38123657

Group type: EXPERIMENTAL
Intervention: Navigate intervention (nurse navigation, patient-reported outcomes, physical exercise)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nurse sessions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Exercise sessions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Overall acceptability of the intervention
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Retention
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Barriers to participation
Number of subjects: 11
Study: 38123726

Group type: EXPERIMENTAL
Intervention: Active transcutaneous spinal direct current stimulation (tsDCS) at 2.5 mA, 3 times/week for 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active tsDCS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 20
Study: 38123759

Group type: EXPERIMENTAL
Intervention: Surgical cure of primary aldosteronism
Number of subjects: 0
Study: 38123762

Group type: EXPERIMENTAL
Intervention: Powered toothbrush usage after instruction and information
Number of subjects: 170

Group type: COMPARATOR
Intervention: Self-reported brush usage
Number of subjects: 170
Study: 38123789

Group type: EXPERIMENTAL
Intervention: Radium-223 + Endocrine Therapy (ET)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo + Endocrine Therapy (ET)
Number of subjects: 382
Study: 38123866

Group type: EXPERIMENTAL
Intervention: Tu'Washindi intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 103
Study: 38123875

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% once daily
Number of subjects: 1025
Study: 38123885

Group type: EXPERIMENTAL
Intervention: Cheneau brace and 18 Schroth Best Practice (SBP) exercise sessions
Number of subjects: 30
Study: 38123922

Group type: EXPERIMENTAL
Intervention: B cell arm (rituximab reinfused upon B cell repopulation)
Number of subjects: 115

Group type: COMPARATOR
Intervention: ANCA arm (rituximab reinfused upon significant rise in ANCA level)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: B cell arm
Number of subjects: 115

Group type: COMPARATOR
Intervention: ANCA arm
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 115
Study: 38123965

Group type: EXPERIMENTAL
Intervention: Regional Impedance Cardiography (RIC)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: RIC monitoring for 72 hours
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: RIC monitoring
Number of subjects: 127
Study: 38123994

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Propranolol (PPL)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL) and Propranolol (PPL)
Number of subjects: 144
Study: 38124076

Group type: EXPERIMENTAL
Intervention: mTBI group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (minor orthopedic injuries)
Number of subjects: 30
Study: 38124084

Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia
Number of subjects: 168

Group type: COMPARATOR
Intervention: Opioid-based anaesthesia
Number of subjects: 168
Study: 38124088

Group type: EXPERIMENTAL
Intervention: AdDIT trial participants from Canada
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: AdDIT trial participants from the UK
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: AdDIT trial participants from Australia
Number of subjects: 629
Study: 38124098

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) iron treatment during early pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral iron treatment during early pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up of offspring from previously randomized mothers
Number of subjects: 0
Study: 38124112

Group type: EXPERIMENTAL
Intervention: Brazikumab (210 mg) administered subcutaneously every 4 weeks for 100 weeks
Number of subjects: 104
Study: 38124133

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) STI testing
Number of subjects: 268

Group type: COMPARATOR
Intervention: STI syndromic management
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: STI diagnosis (positive STI test or reporting STI symptoms)
Number of subjects: 268
Study: 38124155

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy only (PPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with scleral buckle (PPV-SB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride gas (SF6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38124205

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic BP <140mmHg within 30 min)
Number of subjects: 2053

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure management
Number of subjects: 2053

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 2053
Study: 38124230

Group type: EXPERIMENTAL
Intervention: Intra-arterial tenecteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 38124481

Group type: EXPERIMENTAL
Intervention: ONC201 and paxalisib combination treatment
Number of subjects: 0
Study: 38124508

Group type: EXPERIMENTAL
Intervention: Oral swabs collected from participants with early syphilis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lesion swabs collected from participants with early syphilis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral shedding in participants aged 18-29 years
Number of subjects: 32
Study: 38124528

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg orally once daily
Number of subjects: 961
Study: 38124551

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel (mean daily dose of 4 mg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel
Number of subjects: 200
Study: 38124555

Group type: EXPERIMENTAL
Intervention: FA-acetaminophen 1,000 mg (two 500 mg tablets)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: ES-acetaminophen 1,000 mg (two 500 mg caplets)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: LG-ibuprofen 400 mg (two 200 mg capsules)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study: 38125031

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stents (PF-SES)
Number of subjects: 1456
Study: 38125301

Group type: EXPERIMENTAL
Intervention: Lower free triiodothyronine (fT3) levels in patients with ACLD
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Thyroid-stimulating hormone (TSH) levels
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 297
Study: 38125337

Group type: EXPERIMENTAL
Intervention: Self-acupressure educational materials
Number of subjects: 159
Study: 38125671

Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 669

Group type: COMPARATOR
Intervention: VEH-PDT
Number of subjects: 669
Study: 38125672

Group type: EXPERIMENTAL
Intervention: Single-spin PRP preparation (3,000rpm for 15 minutes)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Double-spin PRP preparation (first spinning at 1,500rpm for 6 minutes, continuing at 2,500rpm for 15 minutes)
Number of subjects: 30
Study: 38125722

Group type: EXPERIMENTAL
Intervention: LTX-315 and adoptive T-cell therapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LTX-315
Number of subjects: 6
Study: 38125950

Group type: EXPERIMENTAL
Intervention: Bayesian intravoxel incoherent motion (IVIM) model
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bayesian IVIM model
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cellular proliferative activity marker Ki-67
Number of subjects: 17
Study: 38125963

Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin
Number of subjects: 6412

Group type: COMPARATOR
Intervention: Clopidogrel-aspirin
Number of subjects: 6412
Study: 38126083

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine, placebo, and cognitive behaviour therapy
Number of subjects: 221
Study: 38126181

Group type: EXPERIMENTAL
Intervention: First-line Combined Technique (CoT)
Number of subjects: 362

Group type: COMPARATOR
Intervention: First-line Stent Retriever
Number of subjects: 362
Study: 38126183

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate treatment
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 38126414

Group type: EXPERIMENTAL
Intervention: Oxytocin induction
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no oxytocin induction)
Number of subjects: 88
Study: 38126605

Group type: EXPERIMENTAL
Intervention: Waiting group (T1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-waiting group (T0)
Number of subjects: 120
Study: 38126709

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone 192 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone 384 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NTX levels < 2 ng/mL
Number of subjects: 12
Study: 38126718

Group type: EXPERIMENTAL
Intervention: Immature platelet fraction (IPF)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Immature platelet count (IPC)
Number of subjects: 108
Study: 38126764

Group type: EXPERIMENTAL
Intervention: Sapanisertib 3 or 4 mg daily together with metformin once to three times daily (500-1,500 mg).
Number of subjects: 30
Study: 38126958

Group type: EXPERIMENTAL
Intervention: Consensus panel approach using 3 liver fellowship-trained pathologists scoring histologic parameters.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Interpanel scoring by 3 trained pathologists.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fibrosis scoring by trained pathologists.
Number of subjects: 100
Study: 38127014

Group type: EXPERIMENTAL
Intervention: Dieta Dash application (30 days of use)
Number of subjects: 222
Study: 38127015

Group type: EXPERIMENTAL
Intervention: Inorganic nitrite 40 mg 3 times daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 38127032

Group type: EXPERIMENTAL
Intervention: Leukapheresis materials stored for 0 days
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Leukapheresis materials stored for 1 day
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Leukapheresis materials stored for 2 days
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Leukapheresis materials stored for 3 days
Number of subjects: 3
Study: 38127049

Group type: EXPERIMENTAL
Intervention: Repeated NT-proBNP measurements
Number of subjects: 894

Group type: COMPARATOR
Intervention: Single NT-proBNP measurement
Number of subjects: 894
Study: 38127129

Group type: EXPERIMENTAL
Intervention: Temperature-dependent PBPK model for acetone and toluene with optimized alveolar ventilation (Qp) parameter.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temperature-dependent Qp relationship integrated into the PBPK toluene model.
Number of subjects: 0
Study: 38127151

Group type: EXPERIMENTAL
Intervention: Finnish Children Healthy Eating Index (FCHEI)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Consumption of vegetable oils and vegetable-oil-based margarine (≥ 60% fat)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Consumption of high-fiber grain products
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Consumption of sugary products
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Vegetable, fruit, and berry consumption
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Consumption of low fat (< 1%) milk
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Higher consumption of high-fat (≥ 1%) milk
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Sausage consumption
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Red meat consumption
Number of subjects: 403
Study: 38127188

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 38127212

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Number of subjects: 99
Study: 38127335

Group type: EXPERIMENTAL
Intervention: BEEP followed by WBRT
Number of subjects: 118

Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 118
Study: 38127464

Group type: EXPERIMENTAL
Intervention: Mucus plugs in proximal airway generations
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mucus plugs in larger proximal generations
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Model of airflow resistance due to mucus plugs
Number of subjects: 57
Study: 38127487

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cediranib
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Olaparib and Cediranib
Number of subjects: 120
Study: 38127508

Group type: EXPERIMENTAL
Intervention: FATIGUEWALK (FaW) plus treatment as usual (TAU)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 428
Study: 38127545

Group type: EXPERIMENTAL
Intervention: Arterial lactate index measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 0
Study: 38127586

Group type: EXPERIMENTAL
Intervention: Emicizumab 3 mg/kg maintenance dose every 2 weeks for 52 weeks
Number of subjects: 55
Study: 38127722

Group type: EXPERIMENTAL
Intervention: Dasatinib-Blinatumomab protocol
Number of subjects: 0
Study: 38127780

Group type: EXPERIMENTAL
Intervention: Olaparib plus abiraterone
Number of subjects: 796

Group type: COMPARATOR
Intervention: Placebo plus abiraterone
Number of subjects: 796
Study: 38127845

Group type: EXPERIMENTAL
Intervention: Parent stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 cases
Number of subjects: 0
Study: 38127974

Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Infrainguinal fascia iliaca compartment (FIC) block
Number of subjects: 60
Study: 38128008

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection during pregnancy
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Screening tests for neurodevelopment and other health outcomes
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Blood specimens for SARS-CoV-2 antibody testing
Number of subjects: 2300
Study: 38128154

Group type: EXPERIMENTAL
Intervention: Escitalopram (16-week open-label trial)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Baseline SGK1 expression and hippocampal volume
Number of subjects: 161
Study: 38128401

Group type: EXPERIMENTAL
Intervention: Caregiver emotional reactions at pretreatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Caregiver emotional reactions at mid-treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Child PTS at mid-treatment
Number of subjects: 82
Study: 38128402

Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Mindfulness and gratitude
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Combination of behavioral activation and mindfulness
Number of subjects: 336

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 336
Study: 38128414

Group type: EXPERIMENTAL
Intervention: PepGNP-Dengue (low dose)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PepGNP-Dengue (high dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vehicle-GNP (low dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vehicle-GNP (high dose)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PepGNP-Dengue (both doses)
Number of subjects: 26
Study: 38128460

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO; 40,000 IU/ml)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 59
Study: 38128556

Group type: EXPERIMENTAL
Intervention: BoNTA (200 units)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 200
Study: 38128649

Group type: EXPERIMENTAL
Intervention: Mobile MOUD programs providing same-day access to MOUD
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mobile MOUD programs
Number of subjects: 11
Study: 38128724

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (specific antibiotics not detailed)
Number of subjects: 24
Study: 38128731

Group type: EXPERIMENTAL
Intervention: Intra-uterine tamponnement balloon
Number of subjects: 332

Group type: COMPARATOR
Intervention: Severe PPH
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Low hemoglobin values during severe PPH management
Number of subjects: 332
Study: 38128733

Group type: EXPERIMENTAL
Intervention: Mixed nut consumption
Number of subjects: 28
Study: 38128934

Group type: EXPERIMENTAL
Intervention: 0.01% atropine eye drop once nightly bilaterally for 1 year
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo eye drop once nightly bilaterally for 1 year
Number of subjects: 150
Study: 38129103

Group type: EXPERIMENTAL
Intervention: Orointestinal microbiome
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Classifier for severity with 16 different species and systemic inflammatory response syndrome
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Functional pathway units from GSEA
Number of subjects: 424
Study: 38129116

Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction training (LL-BFRT) at 30% 1-repetition maximum (1-RM) with 70% arterial occlusion pressure
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-load strength training (HL-ST) at 70% 1-RM
Number of subjects: 30
Study: 38129117

Group type: EXPERIMENTAL
Intervention: Telitacicept 240 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Telitacicept 160 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Telitacicept 80 mg
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Telitacicept and Placebo
Number of subjects: 249
Study: 38129136

Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 806

Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 806
Study: 38129357

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 331

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 331
Study: 38129525

Group type: EXPERIMENTAL
Intervention: Berzosertib with radiotherapy (RT) at six dose levels (highest dose 240 mg/m)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Berzosertib with cisplatin and capecitabine
Number of subjects: 34
Study: 38129527

Group type: EXPERIMENTAL
Intervention: Personalized reaching training restricted to the spasticity-free elbow range
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-personalized reaching training
Number of subjects: 46
Study: 38129599

Group type: EXPERIMENTAL
Intervention: Infant cannula
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nasal prongs
Number of subjects: 15
Study: 38129731

Group type: EXPERIMENTAL
Intervention: Warmed IgG 20% 0.4 g/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Warmed IgG 20% 1.0 g/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unwarmed IgG 20% 1.0 g/kg
Number of subjects: 24
Study: 38129775

Group type: EXPERIMENTAL
Intervention: Structured lifestyle and compensatory aid intervention
Number of subjects: 225

Group type: COMPARATOR
Intervention: Education-only self-guided intervention
Number of subjects: 225
Study: 38129778

Group type: EXPERIMENTAL
Intervention: Strain elastography (SE) after one and two cycles of NAC
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Strain elastography (SE) imaging features
Number of subjects: 122
Study: 38129794

Group type: EXPERIMENTAL
Intervention: Blood-based markers and MRI assessments including Muscle Assessment Score, portal flow assessment, magnet resonance elastography, and abbreviated MRI for HCC screening.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Evaluation of lifestyle, muscular strength, physical performance, body composition, and quality of life.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Temporal evolution of biomarkers.
Number of subjects: 150
Study: 38129868

Group type: EXPERIMENTAL
Intervention: Intervention group (INT) received an average of eight intervention sessions (50-90 min) over 6 months
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (TAU)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Intervention group (INT)
Number of subjects: 337
Study: 38129896

Group type: EXPERIMENTAL
Intervention: Task-oriented exercise (12 weeks, 3×60-min per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized resistance and aerobic exercise (12 weeks, 3×60-min per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching control (12 weeks, 3×60-min per week)
Number of subjects: 0
Study: 38129910

Group type: EXPERIMENTAL
Intervention: Real sensorimotor transcranial stimulation (PAS) with robot-assisted therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham sensorimotor transcranial stimulation (PAS) with robot-assisted therapy
Number of subjects: 32
Study: 38130041

Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg with SSRI/SNRI
Number of subjects: 2257

Group type: COMPARATOR
Intervention: Ozanimod 0.92 mg without SSRI/SNRI
Number of subjects: 2257
Study: 38130330

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA)
Number of subjects: 0
Study: 38130375

Group type: EXPERIMENTAL
Intervention: Duloxetine plus exercise (supervised treadmill walking 3 times weekly, duloxetine starting at 30 mg daily titrating to 60 mg daily)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Duloxetine plus exercise
Number of subjects: 9
Study: 38130409

Group type: EXPERIMENTAL
Intervention: Zoliflodacin plus doxycycline combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0